• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.

作者信息

Azzouzi Abdel-Rahmène, Emberton Mark

机构信息

Department of Urology, Angers University Hospital, Angers, France.

Division of Surgery and Interventional Science, University College London, London W1T 7NF, UK.

出版信息

Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.

DOI:10.1016/S1470-2045(17)30163-8
PMID:28368250
Abstract
摘要

相似文献

1
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.帕德立卟吩血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比——作者回复
Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.
2
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.帕利泊芬血管靶向光动力疗法与主动监测治疗低危前列腺癌男性患者（CLIN1001 PCM301）：一项开放标签、3 期、随机对照临床试验。
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.
3
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer.帕德博芬血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究
Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.
4
Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.回复：Padeliporfin 血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期随机对照试验
J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029. Epub 2017 May 10.
5
Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial.关于“Padeliporfin血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期、随机对照试验”的评论
Urology. 2017 Jun;104:7-8. doi: 10.1016/j.urology.2017.03.020. Epub 2017 Mar 22.
6
Photodynamic therapy for prostate cancer - A narrative review.光动力疗法治疗前列腺癌——叙述性综述。
Photodiagnosis Photodyn Ther. 2021 Mar;33:102158. doi: 10.1016/j.pdpdt.2020.102158. Epub 2020 Dec 19.
7
Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.帕德博芬（WST11）血管靶向光动力疗法的适应证扩展：前列腺癌拉丁美洲多中心研究结果
Actas Urol Esp (Engl Ed). 2018 Dec;42(10):632-638. doi: 10.1016/j.acuro.2018.02.009. Epub 2018 Apr 23.
8
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
9
Prostate cancer: Light, camera, action - photodynamic therapy for low-risk disease.前列腺癌：灯光、镜头、开拍——低风险疾病的光动力疗法
Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.1. Epub 2017 Jan 10.
10
Effect of pigmentation on photodynamic therapy - Authors' reply.色素沉着对光动力疗法的影响——作者回复
Lancet Oncol. 2013 Aug;14(9):e340. doi: 10.1016/S1470-2045(13)70359-0.

引用本文的文献

1
The Contemporary Role of Salvage Radical Prostatectomy in the Management of Recurrent Prostate Cancer: An Up-to-Date Review.挽救性根治性前列腺切除术在复发性前列腺癌治疗中的当代作用：最新综述
Life (Basel). 2024 Jul 11;14(7):868. doi: 10.3390/life14070868.
2
Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine.光动力和光热疗法：纳米医学的协同机会。
ACS Nano. 2023 May 9;17(9):7979-8003. doi: 10.1021/acsnano.3c00891. Epub 2023 Apr 27.
3
German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
德国 S3 前列腺癌局部治疗循证指南：首部前列腺癌局部治疗循证指南
Urol Int. 2022;106(5):431-439. doi: 10.1159/000521882. Epub 2022 Feb 10.
4
Focal therapy for primary and salvage prostate cancer treatment: a narrative review.原发性和挽救性前列腺癌治疗的聚焦疗法：一项叙述性综述
Transl Androl Urol. 2021 Jul;10(7):3144-3154. doi: 10.21037/tau-20-1212.
5
Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.血管靶向光动力疗法在泌尿系统恶性肿瘤治疗中的进展。
Molecules. 2020 Nov 19;25(22):5417. doi: 10.3390/molecules25225417.
6
Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.多参数磁共振成像在预测前列腺癌病理结果中的作用
World J Mens Health. 2021 Jan;39(1):38-47. doi: 10.5534/wjmh.200030. Epub 2020 Jun 24.
7
Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities.局限性前列腺癌局部治疗的现状和未来前景：多参数 MRI、MRI-TRUS 融合影像引导活检和治疗方式的发展。
Int J Clin Oncol. 2020 Apr;25(4):509-520. doi: 10.1007/s10147-020-01627-8. Epub 2020 Feb 10.